Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Saved in:
| Title: | Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. |
|---|---|
| Authors: | Torka P; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Akhtar OS; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Reddy NM; Vanderbilt University Medical Center, Nashville, Tennessee., Baysal BE; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Kader A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Groman A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Nichols J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Mavis C; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Tario JD; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Block AW; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Sait SNJ; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Ghione P; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Sundaram S; Icahn School of Medicine at Mount Sinai, New York, New York., Przespolewski ER; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Mohr A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Lund I; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Kostrewa J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., McWhite K; Roswell Park Comprehensive Cancer Center, Buffalo, New York., DeMarco J; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Johnson M; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Darrall A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Thomas-Talley RN; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Wallace PK; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Neppalli V; University of Manitoba, Winnipeg, Manitoba, Canada., Hutson A; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Hernandez-Ilizaliturri FJ; Roswell Park Comprehensive Cancer Center, Buffalo, New York. |
| Source: | Cancer [Cancer] 2022 Apr 15; Vol. 128 (8), pp. 1595-1604. Date of Electronic Publication: 2022 Feb 14. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.34106 |
